Insilico Medicine
Generative AI platform for end-to-end drug discovery, scientific research & longevity
Enterprise·Technical·Powered by Insilico Medicine (proprietary LLLMs)·API available
Key strengths
End-to-end AI-driven drug discovery pipeline (target ID to clinical)Generative chemistry and biology AI (Chemistry42, Generative Biologics)Disease modeling and target discovery via PandaOmicsClinical trial outcome prediction with inClinicoProprietary Large Language of Life Models (LLLMs)
Enterprise pricing
Cambridge, United States
Founded 2014
No ratings yet
- Multi-omics target discovery pipelines — Integrate PandaOmics APIs with internal genomics and proteomics datasets to score and rank disease targets using AI-driven causal inference models.
- Generative molecular design workflows — Feed protein structure inputs into Chemistry42 to generate novel small molecule libraries with predicted binding affinity and ADMET profiles, feeding directly into virtual screening or wet-lab validation queues.
- Clinical success probability modeling — Call inClinico's prediction engine with trial metadata (phase, indication, MoA, patient population) to generate go/no-go decision support scores for portfolio prioritization.
- LLM-powered scientific document generation — Use Science42:DORA to automate literature reviews, IND-section drafting, and competitive landscape analyses using domain-tuned LLLMs.
- AI model benchmarking — Use MMAI Gym and Nach01 benchmarks to evaluate and compare AI models on standardized drug discovery tasks, supporting internal model selection and validation.
- Biologic candidate generation — Deploy the Generative Biologics module to design and optimize antibody or peptide sequences against validated biological targets, with predicted developability scores.